The global quinolones market is expected to have a positive growth curve over the coming years. According to a recent report by Transparency Market Research (TMR), growing prevalence of infectious diseases is projected to lead to growth of the overall quinolones market. The report, titled, “Quinolones Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” discusses the various factors that are accountable for the growth of the overall industry and upcoming market trends.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37247
The rising over-prescription of anti-bacterial drugs has led to an increased resistance to conventional drugs and antibiotics. The synthetic mutation of genes has also increased the resistance levels of antibiotics in the human body. Quinolones form a major class of antibacterial drugs that restrict nucleic acid synthesis. Quinolones exhibit significant bactericidal activity and hence, they have been widely utilized in treating bacterial infections of the skin, the sinuses, the lungs, the stomach, and the urinary tract.
The rising pervasiveness of infectious diseases on account of mutant strains of bacteria is a key factor driving the global quinolones market. Quinolones bring about easier tissue penetration, good oral absorption, and lower side-effects, along with broad-spectrum activity against a number of bacteria strains.
Geographically, North America holds a leading share of the overall quinolones market, on account of the high number of patients infected with these diseases, and the higher ability of consumers to spend on medical treatments. Prominent vendors in the global quinolones market include Allergan, Inc., Bayer AG, Johnson & Johnson, Novartis AG, LG Life Sciences, and Sanofi, among others.